Age and early graft function relate with risk-benefit ratio of allogenic islet transplantation under antithymocyte globulin-mycophenolate mofetil-tacrolimus immune suppression by Lee, Dae Hae et al.
OriginalClinicalScienceçGeneralAge and Early Graft Function Relate With
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Background. Induction therapy with a Tcell–depleting agent followed bymycophenolate mofetil and tacrolimus is presently the
most frequently used immune suppression (IS) regimen in islet transplantation. This study assesses its safety and tolerability in
nonuremic type 1 diabetic recipients.Methods. Fifty-one patients (age, between 29 and 63 years) with high glycemic variability
and problematic hypoglycemia received intraportal islet grafts under anti-thymocyte globulin-mycophenolate mofetil-tacrolimus
protocol. They were followed up for over 48 months for function of the implant and adverse events.Results. Severe hypoglyce-
mia and diabetic ketoacidosis were absent in patients with functioning graft. Immune suppressive therapy was maintained for
48 months in 29 recipients with sustained function (group A), whereas 16 patients stopped earlier due to graft failure (group
B) and in 6 for other reasons. Group Awas significantly older at the time of implantation and achieved higher graft function at post-
transplantation month 6 under similar dose of IS. Prevalence of IS-related side effects was similar in groups A and B, occurring
predominantly during the first year posttransplantation. IS-related serious adverse events (SAE) were reported in 47% of patients,
with 4 presenting with cytomegalovirus infection and 4 (age, 42-59 years) diagnosed with cancer. Except in 1 patient with cancer,
all SAEs resolved after appropriate treatment.Conclusions. These risk/benefit data serve as a basis for clinical decision-making
before entering an intraportal islet transplantation protocol. A longer benefit is observed in recipients of higher age (≥40 years), but
it is not associated with more side effects and SAE.
(Transplantation 2017;101: 2218–2227)For type 1 diabetic patients with problematic hypoglyce-mia, islet transplantation represents a possibility of ther-
apy.1-3 However, the risk-benefit ratio needs to be determined.
This is not easy in view of the heterogeneity of the recipientsReceived 24 June 2016. Revision received 29 August 2016.
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Copyright © 2017 Wolters Kluwerand in the transplant protocols. Single-center protocols usually
have standardized follow-up of graft function, metabolic con-
trol, and safety outcomemeasurements.2,4-7 Because of the lim-
ited number of patients per center, analysis is often conducted in
a combination of preuremic and kidney transplant recipients
and of patients under different immunosuppressive regimens.8
In Belgium, a collaborative Islet Transplant Network wasThe authors declare no conflicts of interest.
D.L., B.K. and P.G. contributed to the study design, literature search, data
collection, data analysis and interpretation and writing of the article. R.H., U.V.d.V.,
and Z.L. researched data and reviewed the article. D.J.T.T., G.M. contributed to
data research and reviewing of the article. B.L., C.D.B., L.C. contributed to the
patient recruitment, data research, and reviewing of the article. C.M. researched
the data and reviewed the article. D.P. contributed to the discussion and editing of
the article. P.G. and B.K. are the guarantors of this work and, as such, had full
access to all the data in the study and take responsibility for the integrity of the
data and the accuracy of the data analysis.
Clinical Trial registration: ClinicalTrials.gov NCT00623610 and NCT00798785.
Correspondence: Pieter Gillard, Department of Endocrinology Herestraat 49, 3000
Leuven and Diabetes Research Center, Laarbeeklaan 103, 1090 Brussel, Belgium.
(Pieter.gillard@uzleuven.be).
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
ISSN: 0041-1337/17/10109-2218
DOI: 10.1097/TP.0000000000001543
Transplantation ■ September 2017 ■ Volume 101 ■ Number 9
 Health, Inc. All rights reserved.
© 2017 Wolters Kluwer Lee et al 2219formed,with islets being isolated in the central isolation facilities
of the Diabetes Research Center of the Vrije Universiteit Brussel
and transplantations being performed by a collaborative team
in 2 Belgian academic centers.6 The present study examines
risk-benefit ratio of well-characterized human islet cell grafts
in nonuremic type 1 diabetic patients receiving immune sup-
pressive therapy that consists of antithymocyte globulin (ATG)
as induction and mycophenolate mofetil (MMF) plus tacroli-
mus (Tac) as maintenance. This combination of Tcell depletion
andMMF-Tac is currently the most frequently used regimen in
islet transplantation9 and has been used in our program for
more than 15 years.10MATERIALS AND METHODS
Graft Recipients
Data were collected from a total of 51 islet β cell recipients
with type 1 diabetes mellitus complicated by hypoglycemia un-
awareness, transplanted between December 2001 and March
2011. Baseline patient characteristics are shown in Table 1.
The recipientswere included according to the following criteria:
(1) Nonsmokers aged between 18 and 65 years; (2) C-peptide
negativitydefinedasplasmaC-peptide<0.09ng/mLatglycemia
of 120 to 200 mg/dL; (3) signs of chronic diabetic complica-
tions (microalbuminuria despite optimal dose of angiotensin-
converting enzyme inhibitor, retinopathy, or hypoglycemic
unawareness); (4) large within-person between-day variation
in fasting self-monitored plasma glucose (defined by coefficient
of variation fasting glycemia [CVfg] ≥25% and HbA1c ≥7%
or 53 mmol/mol despite 4 daily subcutaneous insulin injections
or pump therapy. Female patients of childbearing potential
were excluded. Ethics committee of the Belgian Diabetes
Registry and the participating university hospitals approved
the protocol. This studywas performed according to the Decla-
ration of Helsinki and institution review board approval was
obtained (institutional review board protocol BK/3 and BK/136;
clinicaltrials.gov NCT00623610 and NCT00798785). A
written informed consent was obtained from every patient.
Preparation of Islet Cell Grafts and Transplantation
Isolation and preparation of islet β cell allografts was as de-
scribed previously.6 The technique to access the portal vein
depended on the expertise of the site where patients were
transplanted, either by laparoscopy (University Hospital
Brussels11) or by percutaneous fluoroscopic-guided trans-
hepatic injection (University Hospital Leuven12). In total,
91 grafts were transplanted, of which 41 grafts (n = 22 patients)
were transplantedby laparoscopicand50grafts (n=29patients)
by percutaneous cannulation of the portal vein. Twelve
patients received 1 implant, and 38 patients received 2 implants
within 3 months (interquartile range [IQR], 2.4-3.5 months)
after the first implantation and 1 patient received 3 implants
(at 2.5 and 5 months posttransplantation [PT]). Based on a
possible beneficial effect of intravenous heparin infusion peri-
transplant as reported by Koh et al,13 heparin was adminis-
tered in 3 patients undergoing laparoscopic implantation
at 70 U/kg using continuous infusion of heparin containing
saline (10 U/mL) at 500 U/h (50 mL/h) up to 24 hours PT.
After intra-abdominal bleeding in 2 of the 3 cases, heparin ad-
ministration was removed from the protocol. Doppler ultraso-
nography of the portal vein and liver was performed within
24 hours PT to rule out bleeding and thrombosis.
βCopyright © 2017 Wolters Kluwer HImmune Suppression and Monitoring
The immune suppression (IS) regimen consisted of induc-
tion therapy with ATG (Fresenius; Fresenius, HemoCare,
Redmond, WA) and maintenance therapy with MMF
(Cellcept; Roche, Basel, Switzerland, n = 46) or mycopheno-
lic acid (Myfortic; Novartis, Basel, Switzerland, n = 5) and
Tac (Prograf(t); Astellas Pharma Europe, Staines, UK). First
dose of ATGwas given at day 4 (n = 21) or day 1 (n = 30) be-
fore the first implantation (9mg/kg) and continued at 3mg/kg
for 6 days if T-lymphocyte count was above 50/mm3. No ad-
ditional ATGwas administered at the second or third implan-
tation. MMF (2 g/d) or mycophenolic acid (1440 g/d) was
started together with the first ATG injection and maintained
at this dose, unless clinically necessary. All 5 patients whowere
started with mycophenolic acid were switched over to MMF
within the first year after transplantation, according to avail-
ability. Patients received Tac from day 2 (n = 33) or day 5
(n = 18) at a dose to achieve serum trough levels of 8 to
10 ng/mL first 24 months and 6 to 8 ng/mL thereafter. Two
hours before the first ATGadministration and before eachβ cell
graft, 500 mg methylprednisolone was given intravenously.
Anti-infectiousprophylaxis consistedof valganciclovir (Valcyte
900 mg daily; Roche) and sulfamethoxazole/trimethoprim
(Bactrim Forte 800mg/160mgdaily, Roche) during 100 days af-
ter each implantation.
Assessment of Side Effects and Adverse Events
Outpatient follow-up was performed weekly until PT
week 6, and every 2 weeks between PTweeks 6 and 12 and
monthly thereafter. At each visit, a questionnaire was com-
pleted with a listing of possible adverse events (AEs) and side
effects, followed by a physical examination. Blood work was
done for hematology, kidney and liver function, metabolic
parameters, Tac trough levels (Tacrolimus II, IMx Abbott;
Abbott Laboratories, Wiesbaden, Germany) and cytomega-
lovirus polymerase chain reaction (Amplicor cytomegalovi-
rus [CMV] test; Roche Diagnostics). AEs were assessed and
recorded following the Common Terminology Criteria for
Adverse Events v3.0 (CTCAE), as recorded in the Clinical
Islet Consortium,14 with the grading scale of 1, mild; 2, mod-
erate; 3, severe; 4, life-threatening; and 5, death. Serious AEs
(SAE) were defined as fatal, life-threatening, causing disabil-
ity, causing or prolonging hospitalization, occurrence ofmalig-
nancy or congenital anomaly, and requiring intervention to
prevent permanent impairment or damage.15 The relationship
between each AEs and transplant protocol was categorized by
causality; definitely related, probably related, possibly related,
probably not related, not related, and unknown. Events re-
ported from grade 2 to 5 were included in our analysis.
Assessment of Metabolic Control and Acute
Diabetic Complications
PlasmaC-peptide, glycemia, andHbA1c concentrationswere
measured in the central laboratory of the Belgian Diabetes Reg-
istry.6 All patients performed 4-point to 7-point glycemia pro-
files of home blood glucose monitoring. CVfg was calculated
using the glycemia measured from home blood glucose moni-
toring defined as the ratio of the standard deviation (δ) to the
mean (μ): CVfg = δ/μ. Insulin dose-adjusted A1c (%)was calcu-
lated using HbA1c (%) + (4  insulin dose [U/kg per day]).16
Graft failure was defined as consecutive random plasma
C-peptide less than 0.2 ng/mL measured at glycemia of 120ealth, Inc. All rights reserved.
TABLE 1.
Patient and graft characteristics
Immune therapy 48 mo Stop during 48 mo
Graft failure Other reasons
n 29 16 6
General
Male/female 17/12 9/7 3/3
Body weight, kg 66 (63-70) 70 (67-77) 69 (63-76)
BMI, kg/m2 23 (22-25) 24 (22-26) 25 (23-28)
Age at first islet transplantation, y 46 (40-54) 37 (32-43)a 50 (44-55)
Diabetes
Age at clinical onset, y 15 (12-26) 11 (8-22) 30 (14-37)
Duration of disease, y 28 (24-38) 23 (20-29) 17 (12-42)
Positivity for ICA/GADA/IA2A/I(A)A 5/13/7/26 3/3/6/14 0/2/2/6
≥ 1 Autoantibody positivity (%) 97 94 100
Autoantibody negative (%) 3 6 0
HbA1c, % 7.5 (6.9-8.2) 8.1 (7.4-8.8) 7.8 (7.3-8.3)
Insulin dose, IU/d 34 (28-42) 42 (32-58) 39 (32-54)
Insulin dose, IU/kg per day 0.55 (0.42-0.63) 0.58 (0.52-0.79) 0.56 (0.49-0.72)
IDAA1c, % 9.4 (9.0-10.4) 10.6 (9.5-11.3)b 10.1 (9.4-10.8)
CV fasting glycemia, % 46 (40-50) 47 (41-55) 49 (37-54)
Microvascular complications
Diabetic retinopathy (yes) 25 12 3
Microalbuminuria (yes) 4 4 3
Macrovascular complicationc 14 4 2
Graft
Culture time, d 5 (3-10) 5 (3-10) 4 (2-7)
No. islet infusions 2 2 2
β-cell number (106/kg body weight) 2.6 (2.3-3.1) 2.7 (2.0-3.3) 2.6 (2.3-3.4)
Cellular composition, %
β cells 29 (22-37) 26 (20-35) 24 (24-33)
α cells 8 (5-11) 7 (5-13) 9 (6-14)
Nongranulated cells 49 (41-61) 52 (41-59) 46 (39-49)
Acinar cells 1 (1-6) 2 (1-5) 3 (1-6)
Dead cells 8 (6-11) 9 (7-11) 8 (7-12)
Data are shown as median (IQR).
Coefficient of variation of fasting glycemia defined by 100  (standard deviation/mean).
Statistical difference between IS continue group versus graft failure group or stopped due to other reasons group (Mann-Whitney U) aP < 0.005, bP < 0.05.
c Macrovascular complication is defined as a combined endpoint (carotid stenosis, coronary heart disease, and arterial stenosis of the lower limbs.
IDAA1c, Insulin dose-adjusted A1c; BMI, body mass index.
2220 Transplantation ■ September 2017 ■ Volume 101 ■ Number 9 www.transplantjournal.comto 220 mg/dL. Hypoglycemic events were defined as blood
glucose levels < 70 mg/dL and were assessed by records of
home blood glucose self-monitoring. Severe hypoglycemia
was defined as an event requiring assistance of a third party
to actively administer carbohydrate, glucagon, or other re-
suscitative actions that may be associated with sufficient
neuroglycopenia to induce seizure or coma.
Diabetic ketoacidosis was defined as hyperglycemia (blood
glucose >200 mg/dL) with metabolic acidosis (venous pH
<7.3 or plasma bicarbonate < 15 mmol/L) and the presence
of ketones in blood or urine. This was documented with the
use of patient reports and hospitalization records.
Implant function and metabolic control data were com-
pared between 2 patient groups, those who remained under
IS until 48 months (group A) and those who stopped IS dur-
ing the follow-up due to graft failure (group B).
Statistical Methods
Data collectedwere for intention-to-treat analysis. All values
are expressed as median and IQR or mean ± standardCopyright © 2017 Wolters Kluwerdeviation when indicated. For the comparison of the baseline
patient characteristics, Pearsonχ2 test was used for categorical
data and Kruskal-Wallis for continuous data in 3 different pa-
tient groups. To assess the difference between different
timepoints during the follow-up, Fisher exact test was used
for categorical data and Mann-Whitney U test was used
for continuous data. All analyses were performed using
SPSS (version 22.0) and the graphics were computed by
using Graph Pad Prism (version 5.0). All reported P values
are 2-sided, and a P value less than 0.05 was considered
statistically significant.RESULTS
Baseline Patient Characteristics of Patients With
Continued and Discontinued Immune
Suppressive Therapy
Of the 51 patients, 29 continued IS for 48 months
(Figure 1). The treatment was stopped earlier in 22 patients Health, Inc. All rights reserved.
© 2017 Wolters Kluwer Lee et al 2221(median duration, 18 months; IQR, 13-34 months), in 16 be-
cause of a failing graft and in 6 for another reason in presence
of a functioning graft. The latter group consisted of 2 patients
diagnosed with cancer (malignant melanoma at month 13 PT;
gastric adenocarcinoma with hepatic metastasis at month 27
PT), 1 suffering from therapy-resistant cytomegalovirus infec-
tion between months 6 and 13 PT, 1 who died at age 61 years
as a consequence of acute cerebral hemorrhage at month 4
PT, and 2 who were disappointed that insulin-independence
was not achieved (months 7 and 10 PT).
All 51 patients exhibited high pretransplant glycemic vari-
ability above 25% (Table 1). Themajority hadmicrovascular
complications, with clinical macroangiopathy in 20 patients.
There were no differences in sex, body weight or body
mass index in the recipients who continued or discontinued
IS. Patients with graft failure were significantly younger
(P = 0.001) and exhibited worse glycemic control at time of
transplantation, shown as corrected insulin dose (higher in-
sulin dose-adjusted A1c16) (P = 0.01).
SAEs
Of the 51 patients, 24 (47%) experienced SAE (Table 2).
Three cardiovascular SAE were considered not to be
study related.
SAE related to the implant procedure were uncommon;
they occurred in 3 of 91 implant procedures (3%): 1 percuta-
neous implant caused severe thoracic pain associated with
pleuroperitoneal irritation at the site of puncture (Table 2).
No significant hemorrhage (defined as a drop in hemoglobin
of more than 2 g/dL, or the need for transfusion or surgery)
was seen after percutaneous islet transplantation. Two lapa-
roscopic procedures were complicated by intra-abdominal
bleeding when heparin injection was administered (2/3).
Both cases received a blood transfusion without need for
reintervention. No portal vein thrombosis or puncture of
the gallbladder occurred in either of the 2 approaches.
Thirty-one cases of IS-related SAE were reported in
19 patients. Four patients presented 2 or more SAE. Two pa-
tients exhibited signs of Tac-related toxicity: 1 with encepha-
lopathy and 1 with nephrotoxicity confirmed by renalFIGURE 1. Flowchart of number of patients on immune suppression th
Copyright © 2017 Wolters Kluwer Hbiopsy, both resolving after dose reduction. The most fre-
quently reported SAE caused by infection was PT CMV infec-
tion, observed in 5 patients (10%) and successfully treated
with antiviral medication and/or reduction of MMF. Four of
these 5 patients were CMV antibody negative before trans-
plantation. The other CMV positive patient had reactivation
of CMVat PTmonth 4. Four of 5 patients developed CMVin-
fection after prophylaxis was stopped. One recipient with de
novo CMV infection needed an additional course of oral
valganciclovir because of persisting CMV PCR titers after IV
ganciclovir. Gastrointestinal infections, possibly related to
the intake of IS, were the most common cause of hospitaliza-
tion, resolving with either antibiotics or supportive therapy.
There were 4 cancers reported; 1 metastasized gastric ade-
nocarcinoma at age 56 years with a fatal outcome at PT
month 45, 1 acral lentiginous malignant melanoma at age
43 years with complete remission after excision and cessation
of MMF-Tac, 1 invasive prostate carcinoma at age 61 years
with complete resolution after total prostatectomy, and 1 in-
vasive rectosigmoid adenocarcinoma at age 47 years with re-
mission after laparoscopic sigmoidectomy and cessation of
MMF. Basocellular or squamous cell skin cancers or other
nonskin cancers were not observed.
Side Effects Are Most Prominent During the First 12
Months PT
During the first 12 months when the IS dose was the
highest, half of the patients experienced side effects but signif-
icantly decreased to 25% thereafter (Table 3).
The most prominent symptoms observed the first year
were gastrointestinal symptoms, mostly pyrosis, nausea and
vomiting, which significantly decreased from the second year
after transplantation (Table 4). Neurological symptoms,
mostly memory impairment and headache were observed in
22% of the patients the first year, but significantly decreased
at the second year and remained present in around 5%of the
patients. Respiratory, musculoskeletal symptoms, as well as
asthenia and skin symptoms, were prominent during the first
year, but also showed a decreasing trend from the second
year until 48 months.erapy after β cell transplantation.
ealth, Inc. All rights reserved.
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TABLE 3.
Percent (%) of patients experiencing at least one adverse event under immune suppression therapy during 48months follow-up
Total 48 months
follow-up
Month
0-12 12-24 24-36 36-48
Number of patients under IS 51 51 38 34 29
Serious adverse events 47% 33% 18% 15%a 3%a
Side effects (signs and symptoms) 57% 51% 26%a 21%a 21%a
Depletion of blood cellsb 100% 100% 66%c 47%c 31%c
Statistically significant reduction of adverse events compared with first year PT (PT month 0-12), aP < 0.05.
b Neutropenia and/or lymphocytopenia and/or anemia and/or thrombocytopenia.
Statistically significant reduction of adverse events compared with first year PT (PT month 0-12), cP <0.001.
© 2017 Wolters Kluwer Lee et al 2223LaboratoryAbnormalitiesAreMost CommonDuring the
First 6 Months
Abnormal liver function tests were observed during the first
month PT,with increases in aspartate transaminase (AST>2.5
times upper limit of normal) in 27% of all patients from me-
dian day 6, quickly resolving at day 9 and alanine aminotrans-
ferase (ALT > 2.5 times upper limit of normal) in 43% from
day 6, resolving at day 12. These abnormalities were not seen
after the second islet infusion (P < 0.001 vs after first implant).
All patients developed a decrease in blood cell counts
(Table 3), consisting of lymphocytopenia (100%), anemia
(67%) and thrombocytopenia (8%) in the first weeks after
first implantation. Blood cell counts normalized thereafter, ex-
cept for lymphocytopenia, which remained present in a third
of the recipients under IS until month 48 PT (Figure 2).
Twenty-five percent of the patients received transfusion for
anemia, but no erythropoietin treatment was required. One
patient required therapy with granulocyte colony-stimulating
factor. No platelet transfusions were given.
Implant FunctionWithMetabolicControl Is Sustained in
29 Graft Recipients
Maximal basal C-peptide levels were reached at 3 to
6 months PT in both the group who continued IS for
48 month (A; n = 29) and those who stopped IS (B; n = 16)
during follow-up due to graft failure (Figure 3). In this pe-
riod, C-peptide levels were twice as high in group A than
those in group B, although after the first implantation (before
month 3), a similar degree of β-cell implant function was
measured in both groups. The insulin dose per kilogram in
group Awas reduced to half the dosage at this time, reaching
nearly a third of the dose per kg of those in group B at
12 months (P = 0.002) (Table 5). After month 12 PT, median
C-peptide levels decreased at a similar pace in both groups.TABLE 4.
Prevalence of side effectsa in nonuremic type 1 diabetic recipie
suppression
Follow-up Patients
PT months n Gastrointestinal Neurological
0-1 51 11 (22) 5 (10)
1-12 51 15 (29) 11 (22)
12-24 38 4 (11)b 1 (3)b
24-36 34 3 (9)b 2 (6)
36-48 29 1 (3)b 2 (7)
a Grade ≥ 2 symptoms in > 5 percent of patients.
Statistically significant reduction of patients experiencing side effects compared with first year PT (PT mon
Copyright © 2017 Wolters Kluwer HA striking inverse relationshipwas observed between implant
function andboth glycemic variability and insulin dose-adjusted
A1c levels. None of the patient experienced ketoacidosis or
severe hypoglycemic events during the entire duration of the
study, whereas this was the case for 6 (group A) and 20 (group
B) patients in the year preceding the transplantation.
Tac trough levels as well as MMF dose were decreased
with time, as defined in our protocol, and there was no signif-
icant difference between groups A and B observed (Table 5).DISCUSSION
This study shows that clinical benefits of islet transplanta-
tion outweigh the AEs of chronic IS in a large group of
nonuremic type 1 diabetic patients. Patients with a function-
ing graft experience less glycemic variability with absence of
severe hypoglycemia or episodes of ketoacidosis, without ex-
posing them to unacceptable risks of chronic IS. This positive
risk-benefit ratio is in line with the results of other groups
2,4,8,17-23 which studied more heterogeneous groups of islet-
alone and islet-after-kidney transplantation recipients and/
or using different IS regimens.
Our patient group received cultured islet grafts6 that were
standardized in terms of β cell number, purity and time frame
of a second transplant. To achieve these objectives, islet β
cells frommore than 1 donorwere combined in each implant.
Immunosuppression consisted of ATG induction and MMF-
Tac maintenance therapy, which is currently the most fre-
quently used worldwide.9
Of the 51 islet recipients, more than half of the patients ex-
perienced at least 1 side effect during the 48-month follow-up.
Both implantation procedures (laparoscopy11 and transcu-
taneous12) were rarely associated with acute complications
so that a negative impact on long-term islet function24 wasnts of long-term cultured islet β cell allograft under immune
Side effects n (%)
Respiratory Musculoskeletal Asthenia Skin
3 (6) 4 (8) 3 (6) 0 (0)
8 (16) 7 (14) 6 (12) 6 (12)
2 (5) 4 (11) 3 (8) 3 (8)
3 (9) 3 (9) 1 (3) 2 (6)
2 (7) 3 (10) 1 (3) 2 (7)
th 0-12), bP < 0.05.
ealth, Inc. All rights reserved.
FIGURE 2. Depletion of blood cells in nonuremic type 1 diabetic re-
cipients of long-term cultured islet β cell allograft under immune sup-
pression. Pre-Tx: pretransplantation.
FIGURE 3. Implant function and metabolic control in diabetic recip-
ients of long-term cultured islet β-cell allograft. Data are shown as
mean ± SEM. Random C-peptide measured when glycemia be-
tween 120 and 220 mg/dL. Group A: under immune suppression
for 48 months, Group B: immune suppression stopped before
48 months due to graft failure. Statistically significant compared with
GroupB *P < 0.05, $P < 0.005. IDAA1c, Insulin dose-adjusted hemo-
globin A1c.
2224 Transplantation ■ September 2017 ■ Volume 101 ■ Number 9 www.transplantjournal.comnot seen in our cohort. AEs related to IS were reported in
57% of patients. They occurred predominantly during
the first year after transplantation, when the patients were
treated with higher doses of MMF-Tac, together with the
cumulative effect of ATG induction therapy and concomi-
tant prophylactic medication. As observed in other trans-
plant protocols,25-29 gastrointestinal and neurological
symptoms, well-recognized side effects of respectively
MMF and/or Tac, were the most frequent in this study.
MMF-related gastrointestinal symptoms rarely needed
hospitalization and resolved after short-term supportive
therapy. The majority of these AE resolved after dose re-
duction of immune therapy and side effects of grade 2 or
more were observed in only a quarter of patients after the
first year. In line with other reports,30-32 the majority of
patients in the present study found the side effects less de-
bilitating when compared with severe hypoglycemic epi-
sodes and unstable metabolic control and were satisfied
with the transplantation.
In all patients, depletion of blood cells was observed in the
first month after the first implant, caused by ATG induction,
start ofmaintenance IS and the administration of valganciclovir
and trimethoprim-sulfamethoxazole. Frequent blood sampling
in the peritransplant period may have aggravated anemia.
Most patients presented with neutropenia during the first
month, but this was not associated with serious infections or
high numbers of opportunistic infections. All patients had pro-
longed lymphocytopenia. The use of lymphocyte-depleting
therapies is a well-recognized risk factor for cytomegalovirus
infection,33-35 explaining the comparable CMV disease inci-
dence in our cohort as in the study of Gala-Lopez et al35
(9% vs 9.5%). It is also in line with lower CMV disease inci-
dence observed in other islet transplant cohorts not using
T cell depletion.4,36 An additional important risk factor
for CMV disease is the use of seropositive organ donors in se-
ronegative recipients,37-39 whichwas the case in 4 of 5 patients
in our study. Except for 1 patient, CMVdisease occurredmore
than 100 days after the transplantation, when prophylactic
valganciclovir was stopped according to our protocol. Extend-
ing the duration of prophylactic therapy might prevent addi-
tional cases as shown after kidney transplantation.40
Cancer is a well-established risk of chronic IS.41 None of
the patients in our cohort developed lymphoma or related
diseases. Four patients with a well-functioning islet graft
were diagnosed with cancer, 3 of them after year 2 PT. InCopyright © 2017 Wolters Kluwer3 patients, diagnosis was made at an early stage, with imme-
diate reduction (prostate cancer, colon cancer) or cessation
(melanoma) of IS and follow-up has been so far uneventful.
One patient died from liver metastasized gastric carcinoma.
Although we cannot rule out the contribution of IS in the
occurrence of this late stage gastric cancer, it is probable
that an underlying pathology was already present before
transplantation. This is probably also the case for the 3 SAEs
due to macrovascular events because they occurred in
the early stages after transplantation (1, 4, and 18 months
PT) in a patient population with already a high incidence
of preexisting macrovascular disease. Nevertheless, our find-
ings emphasize the need for frequent monitoring of islet
transplant recipients.
Another well-known risk of calcineurin inhibitor–based IS
is deterioration of native kidney function in recipients of a
nonrenal organ.42 In a previous study, we already showed
that the use of Tac caused an initial 20% reduction in Health, Inc. All rights reserved.
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2226 Transplantation ■ September 2017 ■ Volume 101 ■ Number 9 www.transplantjournal.comestimated glomerular filtration rate which was reversible after
its discontinuation.43Moreover, the risk-benefit ratio of IS reg-
imen using sirolimus with lower levels of Tac is not better than
IS regimens usingMMFwith higher levels of Tac.44 Our previ-
ous study using sirolimus-Tac or sirolimus alone showed in
patients with preexisting microalbuminuria, a worsening of al-
buminuria that was caused by sirolimus,45 supporting further
use of aMMF-Tac–based regimen in this patient population.43
The most relevant clinical benefit for the patients was the
absence of severe hypoglycemia PT. All patients also had sig-
nificantly better (insulin dose-adjusted) HbA1c and a signifi-
cant reduction in glycemic variability, which are well-known
risk factors both for long-term complications and hypoglyce-
mia.46-49 Although C-peptide levels were comparable to pa-
tients with optimal graft function in other studies,2,7,9
maintenance of insulin independence was similar2 or lower
in our cohort. Although this can be a sign of more rapid de-
cline in β-cell mass, our approach has always been to rapidly
restart insulin if glucose values become abnormal preprandial
or postprandial, leading to early reintroduction of insulin.
The patient group where IS was stopped because of loss of
graft function had similar initial graft function (ie, 0-3
months) as the group that maintained graft function during
48 months. The last group exhibited a twofold rise in graft
function during the 3 to 6 months PT, whereas no increase
in graft function was measured in the patient group that
failedwithin the first 4 years. This is in linewith the publication
by Vantyghem et al,7 emphasizing the importance of optimal
graft function 1 month after the last implant in maintaining
long-term graft function with the Edmonton protocol.
The patient group who became C-peptide negative during
follow-up was significantly younger. There are no surrogate
markers that allow us to examine the possible reasons for this
difference in outcome. MMF and Tac levels were not differ-
ent with the first year PT but the patients with less favorable
outcome were significantly younger and had a significantly
worse baseline glucose control. Because HbA1c was not dif-
ferent at 0 to 3 months PT, we hypothesize that immune-
related factors rather than metabolic factors are responsible
for the worse outcome. It is well established in other organ
transplantation settings that older age is associated with im-
proved transplant survival and lower rates of rejection.50 An-
other reason for worse graft function in younger patients
might be less compliance with the immunosuppressive regi-
men.51,52 Future islet transplant protocols can explore the
risk-benefit ratio of more potent immune suppressive regi-
men, especially in younger subjects.
In our cohort under IS during 48 months, a decline in im-
plant function started already after the first year. It is un-
known whether this decline is due to a reduction in Tac
and/orMMF and/or a limited graft β cell mass that is vulner-
able to metabolic stress. Studies are ongoing that aim to re-
duce the important loss of functional β cells immediately
after intraportal transplantation53-56 (ClinicalTrials.gov
identifier: NCT00789308). A phase 1 study with embryonic
stem cell derived endocrine cells57 has also been started
(ClinicalTrials.gov identifier: NCT02239354); this new cell
source may overcome the barrier of the limited amount of
cells that is available for transplantation when deceased do-
nors are used.
In conclusion, islet transplantation using ATG in combina-
tion with MMF-Tac is safe to use in the long term, with sideCopyright © 2017 Wolters Kluwereffectsmostly limited to the first year with themaintenance of
metabolic benefit in those with good initial graft function.
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